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Abstract
Objective
The aim of this phase 2 trial was to ascertain the feasibility and eﬀect of community-based
aerobic exercise training for people with 2 of the more common neuromuscular diseases:
Charcot-Marie-Tooth disease type 1A (CMT) and inclusion body myositis (IBM).
Methods
A randomized single-blinded crossover trial design was used to compare a 12-week aerobic
training program using recombinant exercise bicycles compared to a control period. The
training occurred 3 times per week in community gyms local to the participants. Support was
available from trained gym staﬀ and a research physiotherapist. The 2 disease groups were
analyzed separately. The primary outcomemeasure was peak oxygen uptake (VO2 peak) during
a maximal exercise test, with secondary measures of muscle strength, function, and patient-
reported measures.
Results
Data from 23 people with CMT and 17 people with IBM were included in the analysis. Both
disease groups had high levels of participation and demonstrated improvements in VO2 peak,
with a moderate eﬀect size in the CMT participants (Cohen d = 0.53) and a strong eﬀect size in
the IBM group (Cohen d = 1.72). No major changes were observed in the secondary outcome
measures. Qualitative interviews revealed that participants valued the support of gym
instructors and the research physiotherapists in overcoming challenges to participation.
Conclusion
Twelve weeks of aerobic training in community gyms was feasible, safe, and improved aerobic
capacity in people with CMT and IBM.
Classification of evidence
This study provides Class II evidence that for patients with CMT type 1A and IBM, an aerobic
training program increases aerobic capacity.
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This phase 2 feasibility trial aims to establish whether
community-based aerobic training is safe, feasible, and can
improve cardiopulmonary ﬁtness in 2 more common neuro-
muscular diseases (NMDs): Charcot-Marie-Tooth disease
type 1A (CMT) and sporadic inclusion body myositis (IBM).
Aerobic deconditioning and secondary disuse muscle atrophy
are common in people with NMD and are a likely consequence
of reduced general activity levels. Investigations of people with
CMT found they are less active than the general population1–3
and are deconditioned, as measured by oxygen uptake during
exercise.4 Similar reductions in aerobic capacity have been
reported in people with idiopathic inﬂammatory myopathy.5
Only 3 underpowered, uncontrolled studies have been con-
ducted in these 2 conditions.6–8 These preliminary studies
indicate positive beneﬁts of aerobic training for people with
CMT and IBM but there is a need for larger trials with
comparison to a control. These early studies were undertaken
in hospital environments with supervision by health pro-
fessionals. For lifelong behavior change, taking exercise away
from the hospital and into community gym facilities may be
a step to encouraging self-management, supporting the tran-
sition from exercise as a medical intervention to a leisure ac-
tivity.9 The feasibility of moving exercise interventions into
leisure facilities is untested in these conditions.
There were 3 stated aims of this study: (1) calculate the eﬀect
of training on aerobic capacity; (2) ascertain whether sup-
ported aerobic training in community leisure facilities is fea-
sible, safe, and acceptable; (3) explore secondary physical and
nonphysical eﬀects of exercise.
Methods
Design
We used a single-blinded crossover design to explore the
eﬀect and feasibility of aerobic exercise training in the com-
munity. This design was used in response to observations in
the ﬁeld that participants are more likely to stay in a study if
they receive treatment.10 These rare diseases are challenging
to recruit, so strategies to retain participants, and reduce the
eﬀect of intersubject variation in smaller samples, were key
factors in this choice of design. We have prior experience of
conducting crossover exercise trials.11
Participants were randomized to 2 groups. Group A un-
derwent a 12-week training period (T1), an 8-week reversal
period to detrain, then a 12-week control period (C2). Group
B went through the control period ﬁrst (C1) and the training
period second (T2). We decided to also include an 8-week
period between C1 and T2 for group B tomaintain blinding of
assessors. People with metabolic syndrome detrain within in
1–2 months,12 older men detrain to baseline in 4 weeks,13 and
people with mitochondrial disease return to baseline aerobic
ﬁtness after 8 weeks.14 From this evidence, 8 weeks was
deemed suﬃcient for the detraining period.
Four assessments were undertaken by blinded assessors to
measure outcomes before and after the treatment and control
periods. It was not possible to blind participants in an exercise
trial where aerobic capacity testing was performed using a bi-
cycle ergometer, similar to the training intervention.
Participants from both disease groups were recruited and par-
took in the trial concurrently, but data were analyzed separately.
Sample size estimate
The primary purpose of this study was to explore eﬀect on
aerobic capacity and feasibility of training, but an estimated
sample size was calculated combining evidence from similar
studies7,8 and our own experience. We estimated an intrasubject
coeﬃcient of variation of 0.2, which translates into VO2 meas-
urements outside the range 17–40 mL/min/kg being extremely
unlikely. Using the approach based on 2 one-sided hypothesis
tests for a 2 × 2 crossover trial, a total sample size of 20 partic-
ipants gave at least 80% power to detect an eﬀect of up to 1.06 in
the ratio of mean VO2 under the treatment and the control
regimes. To account for dropouts, the target sample size was set
at 30 (15 in each treatment sequence) in 2 parallel studies (one
for each condition) with 30 participants each.
Standard protocol approvals, registrations,
and patient consents
This study achieved NHS NRES ethical approval (ref: 11/
LO/0760) and consent for participation was obtained,
recorded, and ﬁled. This study was registered on the ISRCTN
clinical trials registry (ID: 99826269)
Recruitment strategy
Potential participants were recruited from clinics and research
databases of the National Hospital for Neurology and Neu-
rosurgery, plus national clinics of colleagues from the British
Myology Society for people with IBM.
Participants were included in the study if they met the fol-
lowing criteria: clinical and genetic diagnosis of CMT type 1A,
or a clinical diagnosis of IBM, supported by histologic con-
ﬁrmation as per the established Griggs criteria (only Griggs
deﬁnite IBM cases were included); aged 18–80; able to walk
Glossary
CK = creatine kinase; CMT = Charcot-Marie-Tooth disease type 1A; CMTES = CMT Examination Score; IBM = inclusion
body myositis; IBMFRS = IBM Functional Rating Scale; NMD = neuromuscular disease;W = maximum work rate during the
exercise testing.
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for 30 meters with or without a walking aid or orthotic
devices; ability to safely mount/dismount an exercise bike
unaided or with minimal assistance; and signed informed
participant consent.
Exclusion criteria were presence of other signiﬁcant neurologic
disorders or major comorbidities; limb surgery during the 6
months prior to screening (or planned before ﬁnal assessment);
failure to pass the screening assessment for exercise testing; aged
over 80 or under 18 years; concurrent involvement in another
intervention trial; people already participating in moderate to
vigorous aerobic exercise more than 3 times per week; and
women of childbearing age if they were pregnant or planning to
become pregnant during the study.
Randomization
A block randomization method was used to allocate participants
to groups. Block sizes of 4 were used based on random numbers
generated in MATLAB (Mathworks, Cambridge, UK). The
random block sequences were stored on a password-protected
spreadsheet. Allocation to the groupswas input and spreadsheets
held by an unblinded member of staﬀ who were not involved in
screening, recruitment, assessment, or training of the partic-
ipants. This ensured allocation was concealed after enrollment
and consent. Allocation was stratiﬁed according to baseline
disease severity scores. For the Charcot-Marie-Tooth Neurop-
athy Score, categories weremild (0–10), moderate (11–20), and
severe (over 20). For the IBM, the IBM Functional Rating Scale
(IBMFRS) categories were mild (over 28), moderate (14–28),
and severe (0–14).15,16
Intervention
There are no speciﬁc guidelines for exercise training in neu-
romuscular diseases and therefore we adapted the aerobic
training protocols recommended by the American College of
Sports Medicine, considered gold standard for aerobic exer-
cise to maintain health and ﬁtness.17 We also used previous
protocols used in other neuromuscular exercise studies, some
of which were developed by our team.14
Participants trained in their local gyms for convenience and to
increase participation. Weekly sessions with professionally
qualiﬁed ﬁtness instructors were arranged for the ﬁrst month,
then every other week for the second and third months. Fit-
ness instructors received face-to-face training in the in-
tervention protocol by the research physiotherapist, and
received a training manual. The research physiotherapist
visited the gym at the beginning and midpoint of the training
period, and conducted a telephone review every 2 weeks.
Extra calls or visits were made where either the participant or
the ﬁtness instructor identiﬁed a need for more support.
Participants exercised on a bicycle ergometer 3 times per week
for 12 weeks (36 sessions) working towards a duration of 30
minutes. All had heart rate monitors to set training targets.
Initially the target heart rate corresponded to 60% of VO2
peak. The intensity was progressively increased to 70% after 4
weeks and 80% after 8 weeks. Target heart rates were calcu-
lated using the standard formula: 220 minus the participant’s
age. We found in some weaker participants that they struggled
to meet the heart rate training levels. In these cases, we used
the BORG perceived exertion ratings to ensure they were
training at a suﬃciently high intensity.
Each exercise session began with a 5-minute warm-up on the
bicycle ergometer and ended with a 5- to 10-minute cool-down
period. Participants were encouraged to exercise on alternative
days to allow time for recovery and reduce general orthopedic
stress.17 Exercise participation and symptoms such as fatigue,
pain, and mood were recorded using an exercise diary. Diary
completion was monitored by the research physiotherapist
during fortnightly phone calls and a midway gym visit.
For the control and detraining period, participants were asked
to continue their normal, prestudy activity levels. They con-
tinued to complete the exercise diary and were encouraged to
complete any additional exercise or activity they had done.
Participants had a monthly telephone review during the
control period where general activity, fatigue, pain, and mood
were recorded.
Primary outcome
The primary outcome measure was maximum aerobic ca-
pacity measured as peak oxygen uptake (VO2 peak) during
a symptom-limited progressive exercise test on a semi-
recombinant bicycle ergometer. Oxygen uptake wasmeasured
using indirect calorimetry (Cortex Metalyzer, Biophysik,
Leipzig, Germany).
Prior to undertaking a maximal exercise test, participants
underwent screening to ensure there was no evidence of
cardiac dysfunction and therefore minimal risk of cardiac
events during the protocol. ECG and blood pressure were
monitored before, during, and after the test.
Secondary outcomes
A battery of body structure and function, impairment, activity,
and self-reported measures was used to ascertain additional
eﬀects of the aerobic training. Body structure and function
measures were as follows: body mass index (BMI) and per-
centage body fat, measured using skin fold calipers; blood
pressure and lung function (hand-held spirometry); fatigue
severity using the Fatigue Severity Scale; pain, using a visual
analogue scale; and isometric and isokinetic lower limb
muscle function, using Cybex HUMAC dynamometer. Ac-
tivity measures were maximum work rate during the exercise
testing (W); 10-meter timed walk; 6-minute walk distance;
and perceived walking function using the Walk-12 scale plus
physical activity measured using Sensewear activity monitors
for 1 week at the start of the trial and 1 week at the end of the
training phase. Disease-speciﬁc measures were used to as-
certain impairment and disability: CMT Examination Score
(CMTES) for participants with CMT and the IBMFRS for
participants with IBM. Other measures were self-eﬃcacy for
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managing chronic diseases (6-item scale); barriers to activity
and exercise; Short Form–36 quality of life measure; Pitts-
burgh Sleep Quality Scale; Epworth Sleepiness Scale; and
International Physical Activity Questionnaire.
Safety monitoring
During the training and control periods, participants recorded
pain and fatigue levels using visual analogue scales. This was
monitored by the research team during telephone reviews and
the measurement sessions. Blood creatine kinase levels were
recorded at each of the measurement sessions to monitor any
change that could be indicative of muscle damage.
Statistical analysis
The main analysis was descriptive as this phase 2 exploratory
study was not powered for eﬃcacy, and the size of eﬀect was
calculated for the primary outcome only. Means and SDs were
calculated for continuous and interval data, with medians and
interquartile ranges used for categorical measures. Missing
data postintervention were imputed using a missing at ran-
dom assumption. Where preintervention primary outcome
data were missing (e.g., if participants were unable to undergo
exercise testing due to raised blood pressure), the data for that
individual were not included in the eﬀect size analysis. We
calculated the size of the eﬀect of training on VO2 peak using
both the Cohen d and Hedges g statistics, to account for any
clustering within individuals. Data for participants who
withdrew partway through the study were included for the
time points prior to their exit.
Qualitative analysis
Study participants were invited for a semi-structured tele-
phone interview once they had completed the ﬁnal assess-
ment. The interviewer was not part of the main intervention
team and was unknown to the participant (A.S.). Questions
centered on attitudes to exercise, experience of being in
the trial, and how the training intervention aﬀected the
participant. The interview was digitally recorded, tran-
scribed, and coded using thematic analysis for emerging
themes.
Post-trial follow-up
All participants were telephoned by the research physiother-
apist 3 months after the cessation of the study to see if they
were continuing to exercise.
Data availability
Any data not published within the article will be shared in an
anonymized format, by request from any qualiﬁed
investigator.
Figure 1 Consolidated Standards of Reporting Trials diagram
Recruitment, enrollment, allocation, and retention details of participants for the (A) (CMT) and (B) (IBM) groups. BP = blood pressure; ITT = intent-to-treat.
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Classification of evidence
This intervention study provides Class II evidence for the
primary research question: What is the eﬀect of community-
based aerobic exercise training (for 12 weeks, 3 times a week
at 80% of maximum heart rate) on aerobic capacity in people
with CMT and IBM?
For the secondary aims, this study provides Class II evidence
for the second research question: Is the intervention safe and
acceptable? It also provides Class III evidence for the third
research question: Are there eﬀects on physical function,
lower limb strength, fatigue, sleep, physical and quality of life?
Results
Recruitment
The recruitment target for the CMT group was 30 people
over a 26-month period. In total, 282 people with CMT were
invited to participate and 254 were excluded, refused, or did
not respond. The most common reasons for active exclusion
were coexisting illness or recent limb surgery (60), already ex-
ercising over 3 days per week (32), or unable to meet time
commitments (27). Thirty-one people underwentmore detailed
screening but 3 failed to meet the study criteria. A total of 28
people with CMT enrolled during the study period, giving a re-
cruitment rate of 1.1 per month. Of these 28 people, 5 withdrew
before starting (2 due to time commitments, 2 due to an un-
related injuries, and 1 due to a new cardiac diagnosis) and 3
partway through the study (1 joined a drug trial, 1 knee injury, 1
due to stress). In total, 20 people fully completed the study
protocol, but the data for the 23 people who started the study
were used for analysis using an intention-to-treat approach
(ﬁgure 1).
The recruitment target for the IBM group was 30 people over
a 26-month period. In total, 122 people with IBMwere invited
to participate and 102 were unable to commit to the trial or
did not meet the study criteria on initial screening. The most
common reasons were as follows: too old for the age criteria
(27); did not want to participate (19); coexisting illness (18).
A total of 20 people with IBM enrolled during the study
period, giving a recruitment rate of 0.9 per month. Of these 20
people, 3 withdrew before being randomized (2 due to pre-
existing conditions, 1 was put oﬀ by the control period) and 1
withdrew part way through. In total, 16 people fully com-
pleted the study protocol, but the data for the 17 people who
started the study were used for analysis using an intention-to-
treat approach (ﬁgure 1).
Participant characteristics
The CMT group was signiﬁcantly younger than the IBM
group, and both groups were mildly overweight, according to
the mean BMI (table 1). The proportion of male to female
participants was 58% male in the CMT group and 81% male
in the IBM group. Both groups were moderately aﬀected by
their condition, according to the CMTES for the CMT group
and IBMFRS for the IBM group (table 1). Ta
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Table 2 Outcome measures for Charcot-Marie-Tooth disease type 1A participants, group A and B, at the 4 measurement timepoints
Group A Group B
Pre-training Post-training Pre-control Post-control Pre-control Post-control Pre-training Post-training
VO2 peak, mL/min/kg 22.09 ± 4.32 24.91 ± 3.88 25.14 ± 4.98 23.63 ± 4.03 21.09 ± 5.03 22.40 ± 4.50 22.50 ± 4.77 24.10 ± 5.09
Workload, W 136.36 ± 41.19 153.27 ± 30.72 148.43 ± 27.07 147.25 ± 19.70 127.72 ± 43.91 134.40 ± 40.12 139.00 ± 46.20 151.00 ± 50.97
CMTES 10 (2.5) 10.5 (5.5) 10 (6) 11 (2) 12 (2) 12 (7) 12 (5) 12 (6)
BMI, kg/m2 27.03 ± 2.66 27.22 ± 2.42 27.23 ± 2.37 27.55 ± 2.69 27.51 ± 4.62 27.06 ± 4.15 26.95 ± 4.35 26.92 ± 4.21
Body fat % 24.35 ± 4.82 25.05 ± 4.99 25.62 ± 4.89 25.86 ± 4.68 26.00 ± 6.42 25.31 4.05 26.55 ± 4.71 26.01 ± 4.72
Systolic BP, mm Hg 127.33 ± 22.14 125.92 ± 22.57 126.33 ± 25 124.78 ± 21.19 124.92 ± 21.28 122.91 ± 18.55 126.82 ± 14.59 125.36 ± 19.78
Diastolic BP, mm Hg 78.00 ± 6.74 79.33 ± 5.22 74.89 ± 3.82 78.00 ± 5.94 78.33 ± 6.29 77.45 ± 6.20 79.82 ± 7.32 76.36 ± 7.00
FVC, L 3.14 ± 0.77 3.21 ± 0.77 3.13 ± 0.64 3.14 ± 0.73 3.31 ± 0.96 3.33 ± 1.06 3.47 ± 1.01 3.49 ± 0.96
Fatigue severity (FSS) 33 (22.5) 28 (16.5) 20 (27) 27 (20) 32 (18.5) 25 (18) 29 (17) 25 (18)
Pain VAS 2 (5.5) 0.5 (5.5) 2 (5) 0 (3) 3 (4) 1 (4) 0 (3) 0 (1)
Isometric extensor torque 45°, Nm 112.21 ± 45.67 121.29 ± 36.70 116.61 ± 34.51 116.83 ± 38.47 102.88 ± 46.36 111.77 ± 50.40 114.18 ± 54.00 114.68 ± 59.23
Isometric extensor torque 90°, Nm 121.42 ± 52.35 118.96 ± 46.65 117.39 ± 53.33 115.22 ± 52.22 103.92 ± 52.60 88.45 ± 58.30 101.95 ± 58.81 101.23 ± 59.60
Isometric flexor torque 45°, Nm 65.13 ± 26.74 67.75 ± 20.80 64.94 ± 18.90 61.28 ± 17.39 62.67 ± 25.81 66.18 ± 32.42 67.82 ± 32.57 68.50 ± 34.14
Isokinetic peak extensor torque 30°/s, Nm 95.96 ± 33.49 103.92 ± 29.38 95.89 ± 32.70 97.89 ± 33.88 98.04 ± 52.60 99.54 ± 53.84 98.32 ± 56.20 98.73 ± 57.16
Isokinetic peak flexor torque 30°/s, Nm 49.75 ± 17.24 56.54 ± 15.01 50.78 ± 11.71 49.89 ± 12.41 55.71 ± 25.98 57.59 ± 26.83 57.35 ± 27.68 61.32 ± 28.68
10-m timed walk: self-paced, s 10.18 ± 1.84 9.19 ± 1.23 8.69 ± 0.77 8.61 ± 0.85 9.97 ± 2.17 9.48 ± 2.30 9.75 ± 2.04 9.28 ± 1.91
10-m timed walk: maximum speed, s 7.67 ± 1.92 7.24 ± 1.46 6.81 ± 0.80 6.81 ± 0.94 7.31 ± 1.61 7.32 ± 1.79 7.43 ± 1.81 8.39 ± 3.62
6-min walk distance, m 375.83 ± 81.17 406.00 ± 75.06 423.55 ± 59.28 423.17 ± 58.46 362.14 ± 87.48 380.227 ± 91.52 381.77 ± 85.19 393.95 ± 87.04
Walk-12 38.5 (11) 37.5 (15.5) 38 (16) 35 (15) 34.5 (11.5) 34 (20) 34 (16) 35 (13)
IPAQ sit time, min 300 (165) 240 (180) 360 (300) 330 (330) 420 (165) 390 (180) 450 (240) 420 (300)
Barriers to activity and exercise 3.5 (5) 4.5 (4.5) 4 () 3 (6) 4 (2) 4 (2) 4 (6) 5 (4)
Self-efficacy scale 38 (18) 45 (22) 45 (25) 43 (21) 42 (19.5) 43 (17) 45 (17) 46 (15)
SF-36 96 (8.5) 96.5 (8.5) 94 (8) 93 (8) 101 (9) 104 (10) 100 (7) 98 (8)
Continued
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Participation in training intervention
The training diaries revealed that the CMT group participated
in 76% of total training sessions, and the IBM group com-
pleted 91% of sessions.
Primary outcome
In the CMT group, the diﬀerences with training and control
periods for groups A and B are detailed in table 2 and ﬁgure 2A.
When the training and control data for both groups were com-
bined, therewas an 11.7% improvement inVO2peakwith training
(pre-training 22.00mL/min/kg, post-training 24.52mL/min/kg)
compared to a 0.1% deterioration with the control period (pre-
control 23.06 mL/min/kg, post-control 22.94 mL/min/kg).
The Cohen d and the Hedges g calculations for change in VO2
peak showed moderate treatment eﬀect sizes.
In the IBM group, diﬀerences for each group are detailed in
table 3 and ﬁgure 2B. Combining the training and control data
for both groups showed a 17.4% improvement in VO2 peak
with training (pre-training 14.00 mL/min/kg, post-training
16.44mL/min/kg) compared to a 1.3% deterioration with the
control period (pre-control 14.94 mL/min/kg, post-control
14.75 mL/min/kg). The eﬀect sizes for training vs no-training
were strong (table 4).
Secondary outcomes
In the CMT group, when the training and control data for
both groups are combined, there was a 13.1% improvement in
work rate with training (pre-training 137.62 W, post-training
152.19W) compared to a 1.5% improvement with the control
period (pre-control 135.78 W, post-control 140.11 W). Dif-
ferences between the 2 groups are detailed in table 2 and
ﬁgure 2C. The IBM group also demonstrated changes in work
rate when group data was combined. They had a 17.3% im-
provement with training (pre-training 59.87, post-training
70.25 W) compared to a 0.4% improvement with the control
period (pre-control 63.00, post-control 63.25W). Diﬀerences
between the 2 groups are detailed in table 3 and ﬁgure 2D.
There were no major diﬀerences with training observed in the
other secondary measures for the CMT and IBM participants
(tables 2 and 3). A notable challenge when using the iso-
kinetic dynamometer for very weak muscles, particularly the
quadriceps muscles for the patients with IBM, was the diﬃ-
culty some participants found in generating suﬃcient torque
to trigger the motor. This may have aﬀected the reliability of
the dynamometry data.
Activity monitors administered for 7 days at the start and end of
the trial showed no changes in physical activity duration over 3
metabolic equivalent tasks (CMT: pre-trial 2,490 ± 492minutes,
post-trial 2,390 ± 417; IBM: pre-trial 2,336 ± 480 minutes, post-
trial 2,420 ± 424) or other physical activity variables.
Safety monitoring
There were no increases in serum creatine kinase (CK) at
group or individual level with exercise training in bothTa
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conditions. There were also no changes in energy, mood, or
fatigue as recorded via the visual analogue scales in the
training diaries.
Continuation of training
All participants were contacted by telephone 3 months after
the trial. Contact was successfully made with 16 of the CMT
participants. Eight of the 16 were still exercising, but of those
who had stopped, time and work commitments were the most
common reason given. Twelve participants with IBM were
successfully contacted. Only 5 of the 12 were still exercising.
Of the 7 who had stopped, various reasons were given, such as
gym expense and access, lost conﬁdence, time pressures, and
one case of an injurious fall.
Qualitative results
A total of 46 participants agreed to be interviewed following
the trial, 32 with CMT and 14 with IBM. The experiences
were common to both conditions and the following themes
were identiﬁed from the data: reasons for participating in the
trial; expectations; experience of participating in the trial;
support; outcomes of exercise (table 5). Participants took part
for altruistic and personal reasons, with the expectation that
they would beneﬁt. They expected improvements from par-
ticipating in exercise and found participation in the trial ac-
ceptable. Some participants experienced physical challenges
and stressed the importance of the gym instructors and re-
search team. Overall, they described positive outcomes of the
exercise intervention and expressed a desire to continue ex-
ercising, though stated that gym membership costs could be
a barrier.
Discussion
It was encouraging that delivering community-based aerobic
training in leisure-based exercise facilities was achievable. The
excellent participation rates indicate that the approach is
feasible for people with CMT and IBM; however, the low rate
of continuation following the study, compared to a review of
follow-up participation in other disabilities,18 indicates that
self-motivation alone may not be suﬃcient for people with
NMDs to continue independently. The qualitative ﬁndings
indicated that support of health or exercise professionals and
Figure 2 Effect of training and control interventions
Line graphs ofmeanVO2 peak (mL/min/kg) for the Charcot-Marie-Tooth disease type 1A (CMT) group (A); VO2 peak for the inclusion bodymyositis (IBM) group
(B); work rate (W) for the CMT group (C); work rate for the IBM group (D). Error bars are SD, solid lines represent changewith the 12-week intervention/control
periods, dotted lines represent change during the 8-week reversal period at crossover.
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Table 3 Outcome measures for inclusion body myositis participants, group A and B, at the 4 measurement timepoints
Group A Group B
Pre-training Post-training Pre-control Post-control Pre-control Post-control Pre-training Post-training
VO2 peak, mL/min/kg 15.38 ± 3.46 17.00 ± 5.29 16.11 ± 3.37 15.89 ± 3.22 13.63 ± 2.62 13.29 ± 2.63 12.43 ± 2.76 15.71 ± 3.35
Workload (W) 70.63 ± 30.97 79.33 ± 41.06 74.89 ± 34.85 74.78 ± 33.45 49.63 ± 18.47 48.43 ± 24.32 47.57 ± 22.20 58.87 ± 26.89
IBMFRS 31 ( 11) 30 ( 10) 30 (10) 30 (9) 27 (5.5) 25 (10) 25 (11) 25 (11)
BMI, kg/m2 26.73 ± 3.14 26.54 ± 3.41 26.67 ± 3.60 26.56 ± 3.71 25.18 ± 4.45 26.41 ± 3.08 26.34 ± 3.09 26.23 ± 3.25
Body fat % 23.38 ± 5.85 22.20 ± 5.54 22.27 ± 5.48 22.81 ± 6.23 25.41 ± 2.98 26.67 ± 2.27 26.05 ± 2.16 25.53 ± 1.52
Systolic BP, mm Hg 137.78 ± 12.36 132.67 ± 12.61 125.78 ± 16.78 134.00 ± 16.56 125.58 ± 11.49 121.29 ± 10.84 123.00 ± 10.44 125.86 ± 11.96
Diastolic BP, mm Hg 78.89 ± 4.73 80.11 ± 8.65 76.67 ± 10.81 77.38 ± 6.28 78.00 ± 6.55 76.71 ± 7.34 79.57 ± 6.50 79.43 ± 3.69
FVC, L 2.96 ± 0.99 2.83 ± 1.01 2.94 ± 0.94 3.08 ± 1.01 2.81 ± 0.88 3.17 ± 0.95 3.20 ± 0.85 3.12 ± 0.82
Fatigue severity (FSS) 29 ( 29) 31 ( 11) 30 (19) 28 (12) 30 (21) 29 (18) 30 (25) 29 (26)
Pain VAS (average day) 1 ( 2) 0 ( 3) 0 (4) 0 (2) 1.5 (3) 1 (4) 1 (3) 1 (3)
Isometric extensor torque 45°, Nm 39.77 ± 46.18 38.78 ± 41.90 35.11 ± 37.72 35.72 ± 41.45 17.56 ± 23.55 15.43 ± 20.48 16.57 ± 21.62 15.71 ± 20.42
Isometric extensor torque 90°, Nm 36.77 ± 36.62 40.56 ± 40.48 41.33 ± 46.72 40.17 ± 52.05 15.13 ± 11.78 15.00 ± 12.88 15.21 ± 13.02 15.71 ± 13.15
Isometric flexor torque 45°, Nm 54.61 ± 31.93 55.83 ± 28.19 57.72 ± 30.94 58.44 ± 31.87 35.25 ± 11.07 34.36 ± 10.49 36.29 ± 13.66 35.14 ± 14.51
Isokinetic peak extensor torque 30°/s, Nm 33.39 ± 33.66 36.33 ± 36.55 37.83 ± 37.07 33.94 ± 41.13 16.34 ± 13.50 15.21 ± 10.71 15.07 ± 11.79 15.07 ± 11.96
Isokinetic peak flexor torque 30°/s, Nm 35.67 ± 26.36 38.33 ± 24.40 44.11 ± 28.13 42.83 ± 29.79 22.69 ± 8.99 22.93 ± 10.86 20.78 ± 10.33 19.5 ± 10.88
10-m timed walk: self-paced, s 11.31 ± 3.52 10.98 ± 4.05 10.37 ± 3.28 13.44 ± 3.09 13.52 ± 3.53 13.27 ± 4.13 13.04 ± 2.96 13.28 ± 3.97
10-m timed walk: maximum speed, s 9.40 ± 3.94 8.84 ± 3.43 8.62 ± 3.15 8.80 ± 3.41 11.17 ± 3.22 11.19 ± 3.33 13.94 ± 2.39 10.67 ± 3.01
6-min walk distance, m 327.42 ± 92.04 334.33 ± 86.80 338.95 ± 79.96 336.13 ± 84.79 252.22 ± 67.38 260.86 ± 83.55 270.29 ± 77.80 258.93 ± 66.73
Walk-12 41 ( 14) 39 ( 13) 39 (11) 39 (11) 44 (10) 39 (12) 40 (15) 37 (14)
IPAQ sit time, min 300 ( 300) 360 ( 180_) 285 (60) 420 (360) 420 (270) 420 (360) 420 (480) 360 (420)
Barriers to activity and exercise 2 ( 2) 2 ( 2) 3 (1) 1 (1) 3.5 (5.5) 3 (6) 4 (4) 0 (5)
Self-efficacy scale 41 ( 11) 40 ( 16) 49 (17) 41 (15) 48 (15) 47 (10) 47 (19) 46 (12)
SF-36 97 ( 15) 92 ( 8) 95 (9) 93 (10) 90.5 (9.5 90 (10) 93 (6) 92 (8)
Pittsburgh Sleep Quality Scale 6 ( 4) 7 ( 7) 8 (5) 8 (6) 5.5 (3.5) 6 (6) 5 (5) 5 (5)
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free or low-cost gym membership could be key factors in
longer term participation in exercise. This has also been
suggested from exercise trials in other neurologic
conditions.19–21 Safety of exercise has been questioned in
NMDs previously, so the lack of change in serum CK levels,
pain, or fatigue is reassuring.
Both disease groups showed improvement with aerobic
training, with a particularly strong eﬀect of training in the IBM
group. This group was more deconditioned at baseline and
may have had greater potential for improvement, plus they
showed better adherence to the study protocol. Both disease
groups showed better eﬀect sizes than training trials in other
neurologic diseases.22,23 The eﬀect sizes are compelling de-
spite not meeting target recruitment for analysis in the IBM
group. It is worth noting that a priori, there was an un-
derestimation of the intrasubject coeﬃcient of variation of 0.2,
due to an assumption that VO2 measurements outside the
range 17–40 mL/min/kg would be extremely unlikely. In the
IBM group, however, 10 of the 17 participants had baseline
VO2 measures below 17 mL/min/kg and the group mean was
14.5 mL/min/kg. This may have been due to their older age
and potential greater predisposition to sedentary lifestyles.
Although the CMT group presented as ﬁtter at baseline, 3
participants were also below the 17 mL/min/kg threshold.
This may have inﬂuenced the eﬀect sizes in this study, espe-
cially with the small sample, and must be considered when
estimating the sample size of a phase 3 trial. A key aim for
future training trials in IBM will be to see if VO2 peak can be
increased to greater than or equal to 17.9 mL/min/kg, the
threshold for independent community living in older adults.24
The improvement in work rate showed similar magnitudes of
change as VO2 peak, but none of the other secondary meas-
ures showed consistent group changes with the training or
control interventions. The sample size in this study was likely
to be insuﬃcient to show change in some of the functional
measures, but it may also be because the exercise intervention
did not speciﬁcally train leg strength or walking. LargerTa
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Table 4 Summary of effect size statistics for the effect of
aerobic training on VO2 peak compared to the
control condition for the 2 disease groups
Mean SD 2.5% Median (50%) 97.5%
CMT group
Cohen d 0.53 0.28 −0.025 0.53 1.10
Hedges g 0.52 0.28 −0.025 0.51 1.08
IBM group
Cohen d 1.72 0.43 0.89 1.73 2.64
Hedges g 1.68 0.42 0.87 1.68 2.57
Abbreviations: CMT = Charcot-Marie-Tooth disease type 1A; IBM = inclusion
body myositis.
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samples may also be required to ascertain the eﬀect on some
of the nonmotoric factors, such as mood, fatigue, self-eﬃcacy,
and sleep. There are no studies to date that relate these factors
to aerobic capacity in CMT or IBM.
There were limitations and challenges encountered during
this trial that must be considered in the design of a phase 3
study. Recruitment of these rare conditions was a factor,
particularly in IBM, where potential recruits tended to have
more comorbidity and did not pass the safety screening for
maximal exercise testing. To overcome this problem, sub-
maximal exercise tests could be used in a phase 3 trial to
reduce risk to the patient and thus increase the recruitment
pool and provide a more representative sample of patient
populations. Gas exchange threshold and oxygen uptake ki-
netic variables are ideal candidates for future studies as they
are derived from submaximal exercise tests, have been suc-
cessfully utilized as a markers of ﬁtness in many clinical
populations, and are responsive to exercise training.25,26
The crossover design was also a challenge in 2 ways. First,
people were put oﬀ by the prospect of detraining if they were
in the group that exercised ﬁrst. This aﬀected recruitment. In
the CMT group, the VO2 peak did not fully return to baseline
after the 8-week washout period. This will have inﬂuenced the
group means and the eﬀect sizes. If some of the recruitment
challenges are addressed with a multicenter phase 3 trial and
submaximal testing, a more traditional 2-arm design will be
possible and would be preferable to a crossover trial.
To date, this is the largest study of aerobic exercise training in
people with CMT and IBM. The protocol was conducted in
community leisure facilities and demonstrated that a standard
aerobic training program using a bicycle ergometer is feasible,
well-tolerated, and safe for people with CMT and IBM. The
prescribed program had an eﬀect on cardiopulmonary exer-
cise capacity and eﬃcacy will require investigation in larger
trials. Consideration must also be given to the degree of
motivational and ﬁnancial support required for people with
NMDs to exercise on a longer-term basis as part of a self-
management strategy.
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(M.G.H., M.M.R., P.M.M., G.M.R.). M.M.R. received sup-
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Table 5 Summary of themes from qualitative interviews with 46 participants
Main themes Feedback
Reasons for
participating
Most participants were expecting to participate in the trial to learn about their conditions and be able to achieve physical
benefits.
Most participants offered altruistic motives for participation.
Expectations of
participating
Participants expected physical gains from their participation.
Almost all participants felt that exercising regularly would help their condition and that any improvement would lead to
a positive state of well-being.
Experience of trial Most participants described their experiences of the trial as “just fine.”
Some participants experienced physical difficulties during the trial.
Support Participants expressed their positive feelings towards the level of support received.
Families and friends were very supportive of their participation.
All participants described their gym instructors as likeable and helpful professionals.
Participants regarded a free gym membership as a requirement for them to carry on exercising after the trial.
Outcomes of exercise Most participants who expressed positive outcomes from their participation did so regarding their level of fitness. These
participants felt fitter.
Most participants had observed a positive effect on their well-being as a consequence of participating.
Many participants highlighted the positive effect of the exercise on their well-being and mood; some participants specifically
mentioned positive psychological effects while others commented that more psychological support is needed.
The majority of participants expressed a desire to carry on exercising after the trial.
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